Structural and non-coding variants increase the diagnostic yield of clinical whole genome sequencing for rare diseases.
Journal article
Pagnamenta AT. et al, (2023), Genome medicine, 15
Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in bronchiectasis.
Journal article
Shoemark A. et al, (2022), The European respiratory journal
Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in bronchiectasis
Conference paper
Shoemark A. et al, (2022), EUROPEAN RESPIRATORY JOURNAL, 60
The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC).
Conference paper
Seligmann JF. et al, (2022), JOURNAL OF CLINICAL ONCOLOGY, 40
FOXN1 forms higher-order nuclear condensates displaced by mutations causing immunodeficiency.
Journal article
Rota IA. et al, (2021), Science advances, 7
100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care — Preliminary Report
Journal article
Smedley D. et al, (2021), New England Journal of Medicine, 385, 1868 - 1880
Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications.
Journal article
Camps C. et al, (2021), JCO oncology practice, 17, e1162 - e1169
dPCR application in liquid biopsies: divide and conquer.
Journal article
Moreno-Manuel A. et al, (2021), Expert review of molecular diagnostics, 21, 3 - 15
Strategies for increasing diagnostic rate in patients with primary immunological disorders within the Genomics England 100,000 Genomes Project
Conference paper
Camps C. et al, (2020), EUROPEAN JOURNAL OF HUMAN GENETICS, 28, 106 - 106
A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer.
Journal article
Torres S. et al, (2020), Expert review of molecular diagnostics, 20, 575 - 582
The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom
Journal article
Schwarze K. et al, (2019), Genetics in Medicine
Utility of whole-genome sequencing in the clinical diagnostic of rare inherited anaemias
Conference paper
Camps C. et al, (2018), EUROPEAN JOURNAL OF HUMAN GENETICS, 26, 675 - 676
Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series
Journal article
Domingo E. et al, (2018), The Lancet Gastroenterology & Hepatology, 3, 635 - 643
Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease
Journal article
Lenglet M. et al, (2018), Blood, 132, 469 - 483
Isolated erythrocytosis as the first symptom of congenital hypermanganesemia due to homozygous mutation in the SLC30A10 gene
Conference paper
Cario H. et al, (2018), ONCOLOGY RESEARCH AND TREATMENT, 41, 194 - 194
EARLY LESSONS FROM WHOLE-GENOME SEQUENCING IN THE CLINICAL DIAGNOSIS OF RARE INHERITED ANAEMIAS
Poster
Roy N. et al, (2017), HAEMATOLOGICA, 102, 583 - 583
Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer.
Journal article
Valentino A. et al, (2017), Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 19, 651 - 657
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
Journal article
Rosell R. et al, (2017), The Lancet. Respiratory medicine, 5, 435 - 444
Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
Journal article
Santarpia M. et al, (2017), Clinical lung cancer, 18, 178 - 188.e4
European edition of the NCCN clinical practice guidelines: relevance of the translation and adaptation into Spanish.
Journal article
Guillem V. et al, (2017), Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 19, 288 - 290